Hudson Capital Management LLC Makes New Investment in Novartis AG $NVS

Key Points

• Hudson Capital Management LLC made a new investment in Novartis AG, purchasing 2,048 shares valued at approximately $248,000 during the second quarter.
• Several institutional investors and hedge funds have recently increased their stakes in Novartis, with hedge funds collectively owning 13.12% of the company's stock.
• Novartis reported earnings of $2.42 per share for the latest quarter, exceeding expectations and marking a 12.3% year-over-year revenue growth with total revenues of $14.05 billion.

Hudson Capital Management LLC purchased a new position in Novartis AG (NYSE:NVS - Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 2,048 shares of the company's stock, valued at approximately $248,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. GFG Capital LLC purchased a new position in Novartis in the 2nd quarter worth approximately $26,000. WPG Advisers LLC purchased a new position in Novartis in the 1st quarter worth approximately $25,000. Tsfg LLC boosted its holdings in Novartis by 366.0% in the 1st quarter. Tsfg LLC now owns 233 shares of the company's stock worth $26,000 after acquiring an additional 183 shares during the period. Barrett & Company Inc. purchased a new position in shares of Novartis during the 2nd quarter valued at approximately $31,000. Finally, MCF Advisors LLC boosted its stake in shares of Novartis by 66.0% during the 2nd quarter. MCF Advisors LLC now owns 264 shares of the company's stock valued at $32,000 after buying an additional 105 shares during the last quarter. Hedge funds and other institutional investors own 13.12% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Deutsche Bank Aktiengesellschaft restated a "buy" rating on shares of Novartis in a research note on Thursday, August 21st. The Goldman Sachs Group reaffirmed a "sell" rating and issued a $118.00 price target (down from $119.00) on shares of Novartis in a report on Friday, September 12th. Weiss Ratings reaffirmed a "buy (b)" rating on shares of Novartis in a report on Wednesday, October 8th. Morgan Stanley raised shares of Novartis from an "underweight" rating to an "equal weight" rating and set a $123.00 price target on the stock in a report on Friday, August 8th. Finally, Wall Street Zen raised shares of Novartis from a "buy" rating to a "strong-buy" rating in a report on Saturday. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have assigned a Hold rating and three have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $120.33.

Novartis Stock Performance

Shares of NVS opened at $129.31 on Tuesday. The business's fifty day moving average price is $125.37 and its 200 day moving average price is $118.07. Novartis AG has a 12-month low of $96.06 and a 12-month high of $133.55. The stock has a market capitalization of $273.16 billion, a PE ratio of 18.82, a price-to-earnings-growth ratio of 1.80 and a beta of 0.64. The company has a debt-to-equity ratio of 0.53, a current ratio of 0.82 and a quick ratio of 0.62.

Novartis (NYSE:NVS - Get Free Report) last announced its quarterly earnings data on Thursday, July 17th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.38 by $0.04. Novartis had a return on equity of 41.08% and a net margin of 25.64%.The firm had revenue of $14.05 billion for the quarter, compared to analysts' expectations of $13.94 billion. During the same period last year, the business posted $1.97 earnings per share. The firm's revenue for the quarter was up 12.3% on a year-over-year basis. Equities research analysts forecast that Novartis AG will post 8.45 EPS for the current year.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.